Skip to main content
Clinical Trials/NCT05795114
NCT05795114
Recruiting
Not Applicable

Prevention of Perinatal Depression in Birthing People With a History of Adverse Childhood Experiences: A Type 2 Effectiveness Implementation Trial

Northwestern University1 site in 1 country76 target enrollmentJuly 20, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Perinatal Depression
Sponsor
Northwestern University
Enrollment
76
Locations
1
Primary Endpoint
Perinatal depression
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this clinical trial is to evaluate the impact of ROSE in individuals with adverse childhood experiences. The main question it aims to answer is, compared to enhanced treatment as usual, does the delivery of ROSE within a collaborative care model improve depressive symptom trajectories and prevent the development of perinatal depression.

Participants will be randomized to either enhanced treatment as usual or the ROSE intervention, delivered by a care manager within a perinatal collaborative care program. They will complete self-reported surveys of their depression symptoms every 4 weeks to inform their symptom trajectories. They will also complete clinical interviews to establish any incident diagnoses of a major depressive episode.

Detailed Description

The salience of early life experiences during the transition to parenthood underscores the risk of perinatal depression for those with childhood adversity. Mitigation of the adverse effects of childhood adversity via prevention of perinatal depression is an essential component of a reproductive justice-focused public health strategy. Whether and how the collaborative care model can be most effectively leveraged to prevent perinatal depression among pregnant people with a history of ACEs is unknown. To answer these questions, investigators propose a randomized clinical trial of trauma-informed interpersonal therapy modeled after the ROSE intervention and embedded within a perinatal collaborative care program utilizing a type 2 hybrid effectiveness-implementation design.

Registry
clinicaltrials.gov
Start Date
July 20, 2023
End Date
January 31, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emily Miller

Associate Professor

Women and Infants Hospital of Rhode Island

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • At least one prenatal visit at Northwestern Medicine
  • Less than 24 weeks gestation
  • Non-anomalous pregnancy
  • English- or Spanish- speaking
  • ACE score ≥ 2
  • Singleton gestation

Exclusion Criteria

  • Intent to delivery outside of Prentice Women's Hospital
  • Active major depressive episode
  • Active substance use disorder
  • Participation in a study with a competing intervention or outcome

Outcomes

Primary Outcomes

Perinatal depression

Time Frame: Up to 6 months postpartum

Perinatal depression includes any categorical diagnosis of a major depressive episode, assessed using the Longitudinal Interval Follow-Up Examination measured by trained research personnel masked to the intervention

Depression symptoms

Time Frame: Up to 6 months postpartum

Depression symptom trajectories will be measured via Patient Health Questionnaire-9 (PHQ-9) screens administered

Secondary Outcomes

  • Breastfeeding self-efficacy scale(Up to 6 months postpartum)
  • Generalized anxiety disorder(Up to 6 months postpartum)
  • Attachment in adult relationships(Up to 6 months postpartum)
  • Anxiety symptoms(Up to 6 months postpartum)
  • General self-efficacy(Up to 6 months postpartum)
  • Parenting self-efficacy(Up to 6 months postpartum)
  • Perceived stress symptoms(Up to 6 months postpartum)
  • Post-traumatic stress disorder(Up to 6 months postpartum)
  • Emotional support(Up to 6 months postpartum)

Study Sites (1)

Loading locations...

Similar Trials